SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 70 of 83
Word Count: 1441
Character Count: 9267

Document Content:

SFA; or specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. Switzerland The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or this offering may be publicly distributed or otherwise made publicly available in Switzerland.

Neither
this prospectus nor any other offering or marketing material relating to this offering, the Company, the securities have been or will
be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of
securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of securities has
not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded
to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities.

United
Kingdom

The
securities may not be made in the United Kingdom, except that an offer to the public of any securities may be made in the United Kingdom
at any time:

any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus
Regulation;

fewer than 150 natural or legal persons (other than qualified investors as defined under
Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the
Representative for any such offer; or

any other circumstances falling within Section 86 of the Financial Services and Markets Act
2000 (as amended, the “FSMA”);

provided
that no such offer of securities shall result in the requirement for the publication by us of a prospectus pursuant to Section 85
of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.

For
the purposes of this provision, the expression an “offer to the public” in relation to the any securities in the United Kingdom
means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered
so as to enable an investor to decide to purchase or subscribe for the securities, and the expression “UK Prospectus Regulation”
means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

This
prospectus is only being distributed to and is only directed at: (1) persons who are outside the United Kingdom; (2) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”);
or (3) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (ed) of
the Order (all such persons falling within (1)-(3) together being referred to as “relevant persons”). The securities are
only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire the securities will be engaged
in only with, relevant persons. Any person who is not a relevant person should not act or rely on this prospectus or any of its contents.

LEGAL
MATTERS

The
validity of the issuance of the securities offered by us in this offering will be passed upon for us by Ellenoff Grossman &
Schole LLP, New York, New York. The underwriters are being represented by McGuireWoods LLP, New York, New York.

EXPERTS

CPAS, PLLC, our independent registered public accounting firm, has audited our consolidated balance sheets as of December 31, 2025
and 2024, and the related consolidated statements of operations, changes in stockholders’ equity and cash flows for the
years ended December 31, 2025 and 2024, as set forth in their report dated February 9, 2026. We have included
our consolidated financial statements in this prospectus and in this registration statement in reliance on M&K CPA PLLC’s report
given on their authority as experts in accounting and auditing.

WHERE
YOU CAN FIND MORE INFORMATION

have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in
the registration statement or the exhibits filed therewith. For further information about us and the common stock offered hereby, reference
is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus concerning the contents
of any contract or any other document are not necessarily complete, please see the copy of the contract or document that has been filed
for the complete contents of that contract or document. Each statement in this prospectus relating to a contract or document filed as
an exhibit is qualified in all respects by the filed exhibit. The exhibits to the registration statement should be reviewed for the complete
contents of these contracts and documents.

currently do not file periodic reports with the SEC. Upon the completion of this offering, we will be required to file periodic reports,
proxy statements and other information with the SEC pursuant to the Exchange Act. The SEC maintains a website that contains reports,
proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the
website is www.sec.gov.

also maintain a website at www.bioventrix.com. Upon completion of this offering, you may access these materials at our website
free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained
in, or that can be accessed through, our website is not a part of, and is not incorporated into, this prospectus.

INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS

BIOVENTRIX,
INC.

CONSOLIDATED
FINANCIAL STATEMENTS

Years
Ended December 31, 2025 and 2024

and
Report of Independent Registered Accounting Firm

BIOVENTRIX,
INC.

CONSOLIDATED
FINANCIAL STATEMENTS

Years
Ended December 31, 2025 and 2024

Table
of Contents

Report
of Independent Registered Accounting Firm	F- 2

Consolidated
Financial Statements:

Consolidated
Balance Sheets	F- 3

Consolidated
Statements of Operations	F-4

Consolidated
Statements of Changes in Stockholders’ Deficit	F-5

Consolidated
Statements of Cash Flows	F- 6

Notes
to Consolidated Financial Statements	F-7

REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

the Board of Directors and

Stockholders
of Bioventrix, Inc.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated
balance sheets of Bioventrix, Inc. (the Company) as of December 31, 2025 and 2024, and the related consolidated statements of operations,
changes in stockholders’ deficit, and cash flows for the years ended December 31, 2025, and the related notes (collectively referred
to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2025 and 2024, and the results of its consolidated operations and its cash flows
for the two-year period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of
America.

Going Concern

The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in the Note 1 to the financial statements, the
Company has suffered net losses from operations in current and prior periods and the Company has incurred and expects to continue to
incur significant costs in pursuit of its expansion and development plans, which raises substantial doubt about its ability to continue
as a going concern. Management’s plans regarding those matters are discussed in the notes to the financial statements. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are
the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.